Algert Global LLC Has $4.70 Million Position in Amneal Pharmaceuticals, Inc. $AMRX

Key Points

• Algert Global LLC increased its stake in Amneal Pharmaceuticals by 25.7% in Q1, now holding approximately 560,783 shares valued at $4.7 million.
• Institutional investors own 31.82% of Amneal Pharmaceuticals, with notable increases in holdings by Raymond James Financial and Russell Investments Group.
• Amneal Pharmaceuticals' stock is currently priced at $9.26, and despite an EPS of $0.23 that beat estimates, it has a high price-to-earnings ratio of 926.93.

Algert Global LLC increased its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 25.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 560,783 shares of the company's stock after purchasing an additional 114,788 shares during the quarter. Algert Global LLC owned approximately 0.18% of Amneal Pharmaceuticals worth $4,699,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. GAMMA Investing LLC lifted its holdings in shares of Amneal Pharmaceuticals by 5,975.0% during the first quarter. GAMMA Investing LLC now owns 3,159 shares of the company's stock valued at $26,000 after acquiring an additional 3,107 shares during the period. Headlands Technologies LLC bought a new position in shares of Amneal Pharmaceuticals during the first quarter valued at $31,000. Amalgamated Bank lifted its holdings in shares of Amneal Pharmaceuticals by 33.0% during the first quarter. Amalgamated Bank now owns 5,511 shares of the company's stock valued at $46,000 after acquiring an additional 1,367 shares during the period. GF Fund Management CO. LTD. bought a new position in shares of Amneal Pharmaceuticals during the fourth quarter valued at $52,000. Finally, Brevan Howard Capital Management LP bought a new position in shares of Amneal Pharmaceuticals during the fourth quarter valued at $107,000. 31.82% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

AMRX has been the subject of a number of analyst reports. The Goldman Sachs Group initiated coverage on Amneal Pharmaceuticals in a report on Friday, June 6th. They set a "buy" rating and a $12.00 price objective for the company. Wall Street Zen lowered Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, May 13th. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $11.60.

Insiders Place Their Bets

In other Amneal Pharmaceuticals news, EVP Nikita Shah sold 71,694 shares of the business's stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $9.29, for a total transaction of $666,037.26. Following the completion of the sale, the executive vice president directly owned 267,235 shares of the company's stock, valued at approximately $2,482,613.15. The trade was a 21.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Andrew S. Boyer sold 279,244 shares of the business's stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $9.38, for a total value of $2,619,308.72. Following the sale, the executive vice president directly owned 152,426 shares of the company's stock, valued at $1,429,755.88. This represents a 64.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 456,374 shares of company stock valued at $4,239,042. 17.45% of the stock is currently owned by insiders.

Amneal Pharmaceuticals Stock Up 0.6%

AMRX stock traded up $0.06 during midday trading on Friday, reaching $9.59. The stock had a trading volume of 1,720,973 shares, compared to its average volume of 1,726,976. The firm has a market cap of $3.01 billion, a price-to-earnings ratio of 959.96 and a beta of 1.11. Amneal Pharmaceuticals, Inc. has a twelve month low of $6.68 and a twelve month high of $9.79. The business has a fifty day simple moving average of $8.38 and a two-hundred day simple moving average of $8.01.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.17 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 189.49% and a net margin of 0.12%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. On average, equities analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.